Literature DB >> 2374150

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.

R Sarges1, H R Howard, R G Browne, L A Lebel, P A Seymour, B K Koe.   

Abstract

A series of 4-amino[1,2,4]triazolo[4,3-a]quinoxalines has been prepared. Many compounds from this class reduce immobility in Porsolt's behavioral despair model in rats upon acute administration and may therefore have therapeutic potential as novel and rapid acting antidepressant agents. Optimal activity in this test is associated with hydrogen, CF3, or small alkyl groups in the 1-position, with NH2, NH-acetyl, or amines substituted with small alkyl groups in the 4-position, and with hydrogen or 8-halogen substituents in the aromatic ring. Furthermore, many of these 4-amino[1,2,4]triazolo[4,3-a]quinoxalines bind avidly, and in some cases very selectively, to adenosine A1 and A2 receptors. A1 affinity of these compounds was measured by their inhibition of tritiated CHA (N6-cyclohexyladenosine) binding in rat cerebral cortex membranes and A2 affinity by their inhibition of tritiated NECA (5'-(N-ethylcarbamoyl)adenosine) binding to rat striatal homogenate in the presence of cold N6-cyclopentyladenosine. Structure-activity relationship (SAR) studies show that best A1 affinity is associated with ethyl, CF3, or C2F5 in the 1-position, NH-iPr or NH-cycloalkyl in the 4-position, and with an 8-chloro substituent. Affinity at the A2 receptor is mostly dependent on the presence of an NH2 group in the 4-position and is enhanced by phenyl, CF3, or ethyl in the 1-position. The most selective A1 ligand by a factor of greater than 3000 is 121 (CP-68,247; 8-chloro-4-(cyclohexyl-amino)-1- (trifluoromethyl)[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 28 nM at the A1 receptor. The most potent A2 ligand is 128 (CP-66,713; 4-amino-8-chloro-1- phenyl[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 21 nM at the A2 receptor and a 13-fold selectivity for this receptor. Representatives from this series appear to act as antagonists at both A1 and A2 receptors since they antagonize the inhibiting action of CHA on norepinephrine-stimulated cAMP formation in fat cells and they decrease cAMP accumulation induced by adenosine in limbic forebrain slices. Thus certain members of this 4-amino[1,2,4]triazolo[4,3-a]quinoxaline series are among the most potent and A1 or A2 selective non-xanthine adenosine antagonists known.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374150     DOI: 10.1021/jm00170a031

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family.

Authors:  T R Webb; N Melman; D Lvovskiy; X D Ji; K A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2000-01-03       Impact factor: 2.823

2.  Highly selective deuteration of pharmaceutically relevant nitrogen-containing heterocycles: a flow chemistry approach.

Authors:  Sándor B Ötvös; István M Mándity; Ferenc Fülöp
Journal:  Mol Divers       Date:  2010-09-15       Impact factor: 2.943

3.  Adenosine receptors in post-mortem human brain.

Authors:  S James; J H Xuereb; R Askalan; P J Richardson
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

4.  A3-adenosine receptors: design of selective ligands and therapeutic prospects.

Authors:  Kenneth A Jacobson; Hea O Kim; Suhaib M Siddiqi; Mark E Olah; Gary L Stiles; Dag K J E von Lubitz
Journal:  Drugs Future       Date:  1995-07       Impact factor: 0.148

5.  Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation.

Authors:  S V Vellucci; D J Sirinathsinghji; P J Richardson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes.

Authors:  K A Kirkpatrick; P J Richardson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Adenosine receptors mediate both contractile and relaxant effects of adenosine in main pulmonary artery of guinea pigs.

Authors:  A J Szentmiklósi; A Ujfalusi; A Cseppentö; K Nosztray; P Kovács; J Z Szabó
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

8.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.

Authors:  K A Jacobson; C Gallo-Rodriguez; N Melman; B Fischer; M Maillard; A van Bergen; P J van Galen; Y Karton
Journal:  J Med Chem       Date:  1993-05-14       Impact factor: 7.446

9.  125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor.

Authors:  T M Palmer; S M Poucher; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1995-12       Impact factor: 4.436

10.  Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism.

Authors:  O Nikodijević; R Sarges; J W Daly; K A Jacobson
Journal:  J Pharmacol Exp Ther       Date:  1991-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.